FAKHRAVAC

Vaccine against COVID-19

  • Emergency use authorization: IRN
Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
  • COVID-19 (disease)
  • SARS-CoV-2 (virus)
  • Cases
  • Deaths
virus icon COVID-19 portal
  • v
  • t
  • e

FAKHRAVAC (Persian: واکسن فخرا) is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research,[1] a subsidiary of Iran's Ministry of Defense. It is the third Iranian COVID-19 vaccine reaching clinical trials.[1][2][3] It is currently in phase III.[4][5] It received emergency use authorization in Iran on 9 September 2021.[4]

The vaccine is named after the Iranian nuclear scientist Mohsen Fakhrizadeh.[1] According to the Iranian authorities, he was working on a vaccine in response to the COVID-19 pandemic in Iran.[1][6] Fakhrizadeh was assassinated in November 2020 in an attack Iran and US intelligence attributed to Israel.[1][7]

Medical uses

It requires two doses given by intramuscular injection 3 weeks apart.[5]

Pharmacology

FAKHRAVAC is an inactivated virus-based vaccine.[3]

Manufacturing

In August 2021, production capacity of the vaccine was reported to be 1 million dose per month and was planned to be "multiplied in a few months ".[4] In October 2021, the production was reported to be stopped amid Iran's growing vaccine imports.[8] In January 2022, the Director General of Health of the Ministry of Defense announced that the first shipment (around 462,000 doses) of the vaccine had been delivered to the Iranian Ministry of Health.[9]

Clinical trials

Clinical trials of FAKHRAVAC
Phase Registration number Start Number of participants Age of participants
Total Vaccine Control
I IRCT20210206050259N1 Archived 28 April 2021 at the Wayback Machine 8 March 2021 135 96? 39? (placebo) 18–55 years
II IRCT20210206050259N2 Archived 16 June 2021 at the Wayback Machine 8 June 2021 500 250 250 (placebo) 18–70 years
III IRCT20210206050259N3 Archived 7 September 2021 at the Wayback Machine 29 August 2021 41,128 20,564 20,564 (Sinopharm BIBP vaccine) >18 years

Authorizations

FAKHRAVAC received emergency use authorization in Iran on 9 September 2021.[4] In October 2021, Iran's Food and Drug Administration was considering giving full authorization to the vaccine for third/booster dose.[8]

See also

References

  1. ^ a b c d e Motamedi M (16 March 2021). "Iran starts human trials of its third domestic COVID vaccine". Al Jazeera.
  2. ^ "Phase 1, safety, immunogenicity and dose finding for two strengths of 0.5 × 10^6 and 2.5 × 10^6 (TCID50) inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC) injected in two schedules of two doses, 2 and 3 weeks apart in healthy adults aged 18-55 years: a randomized, double blind, placebo controlled, clinical trial". en.irct.ir. Iran Registry of Clinical Trials. Retrieved 21 March 2021.
  3. ^ a b "Phase 2 trial of safety and immunogenicity of 10 micro gram inactivated SARS-CoV-2 vaccine (FAKHRAVAC), two doses two weeks apart in adults aged 18-70 years: a randomized, double-blind, placebo-controlled, clinical trial". en.irct.ir. Iran Registry of Clinical Trials. Retrieved 15 June 2021.
  4. ^ a b c d "Iran Authorizes Emergency Use of Third Homegrown Vaccine - Defense news". Tasnim News Agency. Retrieved 9 September 2021.
  5. ^ a b "IRCT | Comparison of the safety, efficacy and immunogenicity of Fakhravac and Sinopharm SARS-CoV-2 vaccines, in adults aged 18 and over; a phase III randomised, non-inferiority clinical trial". en.irct.ir. Archived from the original on 7 September 2021. Retrieved 7 September 2021.
  6. ^ "Research center run by Fakhrizadeh produced first COVID-19 test kits for Iranians: Defense minister". Pars Today. 28 November 2020. Archived from the original on 5 December 2020. Retrieved 7 September 2021.
  7. ^ The Assassination of Fakhrizadeh: Considerations and Consequences
  8. ^ a b Sinaee, Maryam (19 October 2021). "Iran Defense Ministry's Covid Vaccine Production To Be Discontinued". Iran International. Retrieved 24 October 2021.
  9. ^ "تحویل نخستین محموله واکسن فخرا به وزارت بهداشت". YJC News. 19 January 2022.
Scholia has a profile for FAKHRAVAC (Q107366045).
  • v
  • t
  • e
Development
Classes
Administration
Vaccines
Bacterial
Viral
Protozoan
Helminthiasis
Other
Inventors/
researchers
Controversy
Related
  • v
  • t
  • e
Pre-pandemic
2020
2021
2022
2023 and after
Africa
Northern
Eastern
Southern
Central
Western
Asia
Central/North
East
Mainland China
South
India
By location
Southeast
Malaysia
Philippines
West
Europe
United Kingdom
By location
Eastern
Western Balkans
European Union
EFTA countries
Microstates
North
America
Atlantic
Canada
Caribbean
Countries
British Overseas Territories
Caribbean Netherlands
French West Indies
US insular areas
Central America
United States
responses
By location
Oceania
Australia
New Zealand
South
America
Others
Culture and
entertainment
Arts and
cultural heritage
Education
By country
Sports
By country
By sport
Society
and rights
Social impact
Labor
Human rights
Legal
Minority
Religion
Economic
By country
By industry
Supply and trade
Financial markets
Information
Misinformation
Politics
Political impact
Protests
International relations
Language
Others
Health issues
Medical topics
Testing and
epidemiology
Apps
Prevention
Vaccines
Topics
Authorized
DNA
Inactivated
mRNA
Subunit
Viral vector
Virus-like particles
In trials
Attenuated
  • COVI-VAC (United States)
DNA
Inactivated
RNA
Subunit
Viral vector
Virus-like particles
Deployment
by location
Africa
Asia
Europe
North America
Oceania
South America
Others
Treatment
Monoclonal antibodies
Small molecule antivirals
Specific
General
Institutions
Hospitals and
medical clinics
Mainland China
Others
Organizations
Global
By location
Health
institutes
Pandemic
institutes
Relief funds
People
Medical
professionals
Researchers
Officials
WHO
  • Tedros Adhanom
  • (Director-General of the WHO)
  • Bruce Aylward
  • (Team lead of WHO-China COVID-19 mission)
  • Maria Van Kerkhove
  • (Technical Lead for COVID-19 response)
  • Michael J. Ryan
  • (Executive Director of the WHO Health Emergencies Programme)
By location
Others
Deaths
Data (templates)
Global
Africa
  • Algeria
  • Angola
  • Benin
  • Botswana
  • Burkina Faso
  • Burundi
  • Cameroon
  • Comoros
  • Egypt
  • Eswatini
  • Ethiopia
  • Ghana
    • cases chart
  • Ivory Coast
  • Kenya
  • Libya
  • Malawi
  • Mali
  • Mauritania
  • Mauritius
  • Morocco (including occupied Western Sahara)
  • Mozambique
  • Namibia
  • Nigera
    • cases chart
  • São Tomé and Príncipe
  • Senegal
  • Seychelles
  • Sierra Leone
  • South Africa
    • cases chart
  • South Sudan
  • Sudan
  • Tanzania
  • Togo
  • Tunisia
  • Uganda
  • Zambia
  • Zimbabwe
    • cases chart
Americas
  • Argentina
  • Bolivia
  • Brazil
  • Canada
    • by province
    • vaccinations by province
  • Chile
    • by commune
  • Colombia
  • Costa Rica
    • cases chart
  • Cuba
  • Dominican Republic
  • Ecuador
  • El Salvador
  • Guatemala
  • Haiti
  • Honduras
  • Mexico
    • cases chart
  • Nicaragua
  • Panama
  • Paraguay
  • Peru
  • United States
    • by state
  • Uruguay
  • Venezuela
Asia
  • Afghanistan
  • Armenia
    • Artsakh
  • Azerbaijan
  • Bahrain
  • Bangladesh
    • by division
  • Bhutan
    • cases chart
  • Brunei
  • Cambodia
    • cases chart
    • summary
  • China
    • cases chart
    • confirmed per capita
    • lockdowns
    • by province
    • Hong Kong
    • Macau
  • Cyprus
  • East Timor
  • Egypt
  • Georgia
  • India
  • Indonesia
    • cases chart
  • Iran
    • cases chart
  • Iraq
  • Israel
    • cases chart
  • Japan
    • cases chart
  • Jordan
  • Kazakhstan
  • Kuwait
    • cases chart
  • Kyrgyzstan
  • Laos
  • Lebanon
  • Malaysia
    • cases chart
    • charts
  • Myanmar
    • cases chart
    • summary
  • Nepal
    • cases chart
  • Oman
    • cases chart
  • Pakistan
    • cases chart
  • Philippines
    • cases chart
    • areas of quarantine
    • vaccinations chart
  • Qatar
  • Russia
    • cases chart
    • by federal subject
    • North Asia
  • Saudi Arabia
  • Singapore
  • South Korea
    • cases chart
    • vaccinations charts
  • Sri Lanka
  • Syria
  • Taiwan
    • vaccination charts
  • Tajikistan
  • Thailand
    • cases chart
  • Turkey
    • cases chart
  • United Arab Emirates
    • cases chart
  • Uzbekistan
    • cases chart
  • Vietnam
    • statistics charts
  • Yemen
Europe
  • Albania
  • Austria
    • cases chart
  • Belarus
  • Belgium
    • cases chart
  • Bosnia and Herzegovina
  • Bulgaria
    • cases chart
  • Croatia
  • Cyprus
  • Czech Republic
  • Denmark
    • cases chart
    • Faroe Islands
  • Estonia
    • cases chart
  • Finland
  • France
    • cases chart
  • Germany
    • cases chart
  • Greece
  • Hungary
  • Iceland
    • cases chart
  • Ireland
    • cases chart
  • Italy
    • cases chart
    • statistics charts
    • vaccinations chart
  • Kosovo
  • Latvia
  • cases chart
  • Lithuania
    • cases chart
  • Luxembourg
  • Malta
  • Moldova
  • Monaco
  • Montenegro
  • Netherlands
  • North Macedonia
  • Norway
    • cases chart
  • Poland
    • cases chart
    • by voivodeship
  • Portugal
    • cases chart
  • Romania
  • cases chart
  • Russia
    • cases chart
    • by federal subject
    • North Asia
  • San Marino
  • Serbia
  • Slovakia
    • cases chart
    • by region
  • Slovenia
    • cases chart
  • Spain
    • cases chart
  • Sweden
    • cases chart
  • Switzerland
    • cases chart
  • Turkey
    • cases chart
  • Ukraine
  • United Kingdom
    • Scotland
      • 2020
      • 2021
    • Gibraltar
    • vaccinations chart
      • daily
      • by nation
  • Vatican City
Oceania
  • Australia
    • by state/territory
  • Fiji
  • French Polynesia
  • New Caledonia
  • New Zealand
  • Papua New Guinea
  • Solomon Islands
Others
  • Cruise ships
    • Diamond Princess
Portals:
  • icon Medicine
  • icon Viruses
  • virus icon COVID-19